588 related articles for article (PubMed ID: 25590376)
1. Perspectives on oral pulmonary hypertension therapies recently approved by the U.S. Food and Drug Administration.
Hill NS; Badesch D; Benza RL; D'Eletto TA; Farber HW; Gomberg-Maitland M; Hassoun PM; Preston I
Ann Am Thorac Soc; 2015 Feb; 12(2):269-73. PubMed ID: 25590376
[TBL] [Abstract][Full Text] [Related]
2. Pulmonary arterial hypertension: a review in pharmacotherapy.
Patel BB; Feng Y; Cheng-Lai A
Cardiol Rev; 2015; 23(1):33-51. PubMed ID: 25275717
[TBL] [Abstract][Full Text] [Related]
3. Macitentan for the treatment of pulmonary arterial hypertension.
DuBrock HM; Channick RN
Expert Rev Respir Med; 2014 Aug; 8(4):393-9. PubMed ID: 24998329
[TBL] [Abstract][Full Text] [Related]
4. Perspectives on Oral Pulmonary Hypertension Therapies Recently Approved by the U.S. Food and Drug Administration.
Burger CD
Ann Am Thorac Soc; 2015 Jun; 12(6):959. PubMed ID: 26075561
[No Abstract] [Full Text] [Related]
5. Reply: Perspectives on Oral Pulmonary Hypertension Therapies Recently Approved by the U.S. Food and Drug Administration.
Hill NS; Badesch D; Benza RL; D'Eletto TA; Farber HW; Gomberg-Maitland M; Hassoun PM; Preston I
Ann Am Thorac Soc; 2015 Jun; 12(6):960. PubMed ID: 26075562
[No Abstract] [Full Text] [Related]
6. Advances in targeted therapy for chronic thromboembolic pulmonary hypertension.
Zhang Y; Yu X; Jin Q; Luo Q; Zhao Z; Zhao Q; Yan L; Liu Z
Heart Fail Rev; 2019 Nov; 24(6):949-965. PubMed ID: 31044326
[TBL] [Abstract][Full Text] [Related]
7. Riociguat: a novel therapeutic option for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
Mielniczuk LM; Swiston JR; Mehta S
Can J Cardiol; 2014 Oct; 30(10):1233-40. PubMed ID: 25154043
[TBL] [Abstract][Full Text] [Related]
8. Riociguat: a novel new drug for treatment of pulmonary hypertension.
Makowski CT; Rissmiller RW; Bullington WM
Pharmacotherapy; 2015 May; 35(5):502-19. PubMed ID: 26011143
[TBL] [Abstract][Full Text] [Related]
9. Is distal chronic thromboembolic pulmonary hypertension treatable with PAH targeted drugs?
Cannon JE; Pepke-Zaba J
Semin Respir Crit Care Med; 2013 Oct; 34(5):620-6. PubMed ID: 24037629
[TBL] [Abstract][Full Text] [Related]
10. Riociguat for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
Bishop BM
Am J Health Syst Pharm; 2014 Nov; 71(21):1839-44. PubMed ID: 25320133
[TBL] [Abstract][Full Text] [Related]
11. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial.
Tapson VF; Torres F; Kermeen F; Keogh AM; Allen RP; Frantz RP; Badesch DB; Frost AE; Shapiro SM; Laliberte K; Sigman J; Arneson C; Galiè N
Chest; 2012 Dec; 142(6):1383-1390. PubMed ID: 22628490
[TBL] [Abstract][Full Text] [Related]
12. Riociguat: a review of its use in patients with chronic thromboembolic pulmonary hypertension or pulmonary arterial hypertension.
Garnock-Jones KP
Drugs; 2014 Nov; 74(17):2065-78. PubMed ID: 25352393
[TBL] [Abstract][Full Text] [Related]
13. Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access study.
McLaughlin VV; Jansa P; Nielsen-Kudsk JE; Halank M; Simonneau G; Grünig E; Ulrich S; Rosenkranz S; Gómez Sánchez MA; Pulido T; Pepke-Zaba J; Barberá JA; Hoeper MM; Vachiéry JL; Lang I; Carvalho F; Meier C; Mueller K; Nikkho S; D'Armini AM
BMC Pulm Med; 2017 Dec; 17(1):216. PubMed ID: 29282032
[TBL] [Abstract][Full Text] [Related]
14. Macitentan for the treatment of pulmonary arterial hypertension.
Kholdani CA; Fares WH; Trow TK
Vasc Health Risk Manag; 2014; 10():665-73. PubMed ID: 25473292
[TBL] [Abstract][Full Text] [Related]
15. Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2).
Rubin LJ; Galiè N; Grimminger F; Grünig E; Humbert M; Jing ZC; Keogh A; Langleben D; Fritsch A; Menezes F; Davie N; Ghofrani HA
Eur Respir J; 2015 May; 45(5):1303-13. PubMed ID: 25614164
[TBL] [Abstract][Full Text] [Related]
16. Haemodynamic effects of riociguat in inoperable/recurrent chronic thromboembolic pulmonary hypertension.
Kim NH; D'Armini AM; Grimminger F; Grünig E; Hoeper MM; Jansa P; Mayer E; Neurohr C; Simonneau G; Torbicki A; Wang C; Fritsch A; Davie N; Ghofrani HA
Heart; 2017 Apr; 103(8):599-606. PubMed ID: 28011757
[TBL] [Abstract][Full Text] [Related]
17. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study.
Ghofrani HA; Hoeper MM; Halank M; Meyer FJ; Staehler G; Behr J; Ewert R; Weimann G; Grimminger F
Eur Respir J; 2010 Oct; 36(4):792-9. PubMed ID: 20530034
[TBL] [Abstract][Full Text] [Related]
18. Bosentan or Macitentan Therapy in Chronic Thromboembolic Pulmonary Hypertension?
van Thor MCJ; Ten Klooster L; Snijder RJ; Kelder JC; Mager JJ; Post MC
Lung; 2019 Dec; 197(6):753-760. PubMed ID: 31583452
[TBL] [Abstract][Full Text] [Related]
19. Riociguat for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Results from a phase II long-term extension study.
Halank M; Hoeper MM; Ghofrani HA; Meyer FJ; Stähler G; Behr J; Ewert R; Fletcher M; Colorado P; Nikkho S; Grimminger F
Respir Med; 2017 Jul; 128():50-56. PubMed ID: 28610669
[TBL] [Abstract][Full Text] [Related]
20. Riociguat for the treatment of pulmonary hypertension.
Meis T; Behr J
Expert Opin Pharmacother; 2014 Nov; 15(16):2419-27. PubMed ID: 25260791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]